Literature DB >> 12492504

Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis.

Y C Wong1, N N C Tam.   

Abstract

We had earlier established an animal model of prostate carcinogenesis using a combination of testosterone (T) and 17beta-estradiol benzoate (E2) on Noble rats (Wang and Wong, 1998). In the present study we examined the changes in a number of smooth muscle differentiation markers including smooth muscle alpha-actin and myosin, vinculin, desmin, laminin and vimentin as well as changes in fine structure by electron microscopy. Our immunohistochemical (IHC) studies revealed that smooth muscle cells (SMCs) subjacent to dysplastic (precancerous) sites and carcinoma usually exhibited a preferential loss of myosin, desmin and laminin. However, the expression of alpha-actin and vinculin appeared to be more persistent in most dysplastic or neoplastic sites. The study reaffirmed our earlier observation that there was a concurrent dedifferentiation of surrounding SMCs during the development and progression of prostate carcinogenesis. The structural study revealed that SMC subjacent to epithelial dysplasia displayed a spectrum of derangements. These included the loosening of muscular layers with SMC characterized by their highly irregular external contours with numerous spine-like cytoplasmic projections. There was also a reduction in density of myofilaments and presence of many enlarged caveolae in muscle cells. Additionally, focal discontinuity or disruptions of muscular layer were often observed together with an increase in abundance of fibrous connective tissue. Moreover, the amount of smooth muscle appeared to be inversely correlated with the histologic grade of prostate tumors. In most instances, SMCs were totally absent in the moderately or poorly differentiated tumors and in metastatic tumors in the lung and the small intestine. Stromal muscular deformity was associated with concurrent changes in epithelial cells. Dysplastic epithelial cells were characterized by a reduction in abundance of secretory organelles such as reduction in size of Golgi apparatus, paucity of granular endoplasmic reticulum and secretory vesicles. The nuclei showed typical deformity characterized by deep nuclear membrane foldings. The basal lamina of dysplastic or tumor cells was present although focal structural abnormalities such as reduplication, disruption and smearing were sometimes observed. The present data indicate that derangements of epithelial cells during prostate carcinogenesis are associated with a reduction or dedifferentiation of stromal SMCs. Our results lend support to the hypothesis that transformed epithelium is incapable of maintaining normal differentiation of adjacent muscle. In turn, abnormal stromal, resulting from dedifferentiation or reduction of SMC, may lead to loss of stromal control over epithelial proliferation and differentiation. Consequently, a loss of differentiation in both epithelium and stromal SMCs may be critically involved in hormone-induced prostate carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12492504     DOI: 10.1046/j.1432-0436.2002.700916.x

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  20 in total

1.  Isolation and characterization of an immortalized mouse urogenital sinus mesenchyme cell line.

Authors:  Aubie Shaw; John Papadopoulos; Curtis Johnson; Wade Bushman
Journal:  Prostate       Date:  2006-09-15       Impact factor: 4.104

2.  Exposure to ethinylestradiol during prenatal development and postnatal supplementation with testosterone causes morphophysiological alterations in the prostate of male and female adult gerbils.

Authors:  Ana Paula Silva Perez; Manoel Francisco Biancardi; Rejane Maira Góes; Fernanda Alcântara dos Santos; Sebastião Roberto Taboga
Journal:  Int J Exp Pathol       Date:  2011-02-12       Impact factor: 1.925

Review 3.  A visual-quantitative analysis of fibroblastic stromagenesis in breast cancer progression.

Authors:  Edna Cukierman
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-10       Impact factor: 2.673

4.  Research resource: estrogen-driven prolactin-mediated gene-expression networks in hormone-induced prostatic intraepithelial neoplasia.

Authors:  Neville N C Tam; Carol Y Y Szeto; Johannes M Freudenberg; Amy N Fullenkamp; Mario Medvedovic; Shuk-Mei Ho
Journal:  Mol Endocrinol       Date:  2010-09-22

5.  Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model.

Authors:  Andreas Birbach; David Eisenbarth; Nicolas Kozakowski; Eva Ladenhauf; Marc Schmidt-Supprian; Johannes A Schmid
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

Review 6.  Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction.

Authors:  Abdulmaged M Traish; Irwin Goldstein; Noel N Kim
Journal:  Eur Urol       Date:  2007-02-20       Impact factor: 20.096

Review 7.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

8.  Diabetes induces stromal remodelling and increase in chondroitin sulphate proteoglycans of the rat ventral prostate.

Authors:  Daniele Lisboa Ribeiro; Sebastião Roberto Taboga; Rejane Maira Góes
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

Review 9.  Prostate cancer and Hedgehog signalling pathway.

Authors:  L M Antón Aparicio; R García Campelo; J Cassinello Espinosa; M Valladares Ayerbes; M Reboredo López; S Díaz Prado; G Aparicio Gallego
Journal:  Clin Transl Oncol       Date:  2007-07       Impact factor: 3.405

Review 10.  Caveola-forming proteins caveolin-1 and PTRF in prostate cancer.

Authors:  Zeyad D Nassar; Michelle M Hill; Robert G Parton; Marie-Odile Parat
Journal:  Nat Rev Urol       Date:  2013-08-13       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.